Close Menu

UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.